Artículos de revistas
Adalimumabe no manejo da retocolite ulcerativa inespecífica: Resultados de um estudo multicêntrico observacional Brasileiro
Fecha
2017-10-01Registro en:
Arquivos de Gastroenterologia, v. 54, n. 4, p. 321-327, 2017.
1678-4219
0004-2803
10.1590/s0004-2803.201700000-51
S0004-28032017000400321
2-s2.0-85033588876
S0004-28032017000400321.pdf
4734747821898178
Autor
PUCPR
Universidade de São Paulo (USP)
Universidade Federal do Rio de Janeiro (UFRJ)
Clínica Gastrosaúde
Clínica ESADI
Hospital Nossa Senhora das Graças
Universidade Estadual Paulista (Unesp)
Institución
Resumen
Background – Adalimumab is a monoclonal antibody, tumor necrosis factor-alpha (TNFα) inhibitor that has efficacy for inducing and maintaining remission in moderate-to-severe ulcerative colitis. Real world studies with adalimumab in Latin American ulcerative colitis patients are scarce. Objective – To assess the clinical remission rates in induction and maintenance with adalimumab therapy in ulcerative colitis. Methods – Observational, multicenter and retrospective study on a case series of patients with moderate-to-severe ulcerative colitis under adalimumab therapy. The variables analyzed were: demographic data, previous infliximab status, concomitant drugs, the Montreal Classification, disease activity (Mayo score) at weeks 0, 8, 26 and 52, or until the last follow-up. Clinical remission was defined as a partial Mayo score ≤2 and Last observation carried forward (LOCF) and Non responder imputation (NRI) analysis were used. Results – Thirty-six patients were included in the study. With LOCF analysis, remission rates at weeks 8, 26 e 52 were of 41.7%, 47.2% and 47.2%, respectively. With NRI analysis, remission rates at weeks 8, 26 and 52 were of 41.7%, 41.7% and 27.8%, respectively. Conclusion – Adalimumab was effective in the treatment of moderate-to-severe ulcerative colitis. Clinical remission was observed in approximately 40% of the patients at weeks 8 and 26, and in almost a quarter of the patients after 1 year of follow up.